<DOC>
	<DOC>NCT00329160</DOC>
	<brief_summary>The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD).</brief_summary>
	<brief_title>Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed written informed consent, 20 to 75 years old, Plan to undergo coronary angiography (CAG) or Percutaneous coronary intervention (PCI) and LDLC ≥ 140 mg/dL (untreated patients) or LDLC ≥ 100 mg/dL (treated patients) Acute myocardial infarction within 72 hours after the onset, Heart failure of New York Heart Association (NYHA) Class III or above, Serious arrhythmia, Being treated with LDLapheresis History of serious reaction or hypersensitivity to other HMGCoA reductase inhibitors.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>